Limited time75% off all plans
Get the app

Medication-assisted treatment

Medication-assisted treatment

Medication-assisted treatment

On this page

MAT Fundamentals - The Sobering Start

  • Integrates FDA-approved medications with counseling & behavioral therapies for substance use disorders (SUDs).
  • Primary Goals: ↓ cravings, ↓ withdrawal symptoms, and block euphoric effects from illicit substances.
  • A comprehensive bio-psycho-social approach, not just medication alone; improves treatment retention.

⭐ MAT is the standard of care for Opioid Use Disorder (OUD) and is proven to significantly reduce the risk of fatal overdose.

Opioid Use Disorder - The Opioid Opponents

  • Principle: Pure opioid antagonists that block μ-opioid receptors. Non-addictive, no euphoric effect.
FeatureNaltrexoneNaloxone
Primary UseRelapse PreventionAcute Overdose Reversal
MechanismLong-acting antagonistShort-acting antagonist
AdministrationOral (ReVia), IM injectable (Vivitrol)IV, IM, Intranasal (Narcan)
Key PointMust be opioid-free 7-10 days priorShort half-life; may need re-dosing
Side EffectHepatotoxicity riskPrecipitates withdrawal

⭐ Buprenorphine is co-formulated with naloxone (Suboxone) to deter misuse. When crushed and injected, the naloxone component precipitates immediate, severe withdrawal symptoms, negating the opioid effect.

Naltrexone: Biphasic Dose Response and Mechanisms

Alcohol Use Disorder - Uncorking the Meds

  • First-Line Agents:

    • Naltrexone: A μ-opioid receptor antagonist that reduces alcohol craving and heavy drinking days. Can be given PO or as a long-acting IM injection. ⚠️ Contraindicated with current opioid use or in severe liver failure.
    • Acamprosate (Campral): A glutamate modulator, thought to restore GABA/glutamate balance. Helps maintain abstinence. Ideal for patients with liver disease but requires abstinence at initiation.
  • Second-Line Agents:

    • Disulfiram: Inhibits aldehyde dehydrogenase, causing an aversive acetaldehyde syndrome if alcohol is consumed. Requires strict adherence and high motivation.
    • Topiramate/Gabapentin: Off-label options that can help reduce cravings and overall consumption.

⭐ Naltrexone can be initiated while a patient is still drinking. Acamprosate is started only after abstinence is achieved to help maintain it.

Tobacco Use Disorder - Clearing the Smoke

image

  • Varenicline (Chantix):
    • MOA: α4β2 nicotinic receptor partial agonist; reduces cravings and withdrawal.
    • Highest single-agent efficacy.
    • SEs: Nausea, insomnia, neuropsychiatric symptoms (use with caution).
  • Bupropion (Zyban):
    • MOA: Norepinephrine-dopamine reuptake inhibitor.
    • Good choice for co-occurring depression.
    • ⚠️ Contraindicated in patients with seizure disorders or eating disorders.
  • Nicotine Replacement Therapy (NRT):
    • Forms: Patch, gum, lozenge, inhaler.
    • Strategy: Combine long-acting (patch) with short-acting (e.g., gum) for breakthrough cravings.

⭐ Combination NRT (patch + short-acting form) and varenicline are the most effective FDA-approved smoking cessation treatments.

High‑Yield Points - ⚡ Biggest Takeaways

  • Opioid Use Disorder (OUD): Treat with methadone (long-acting agonist, QTc risk), buprenorphine (partial agonist, ceiling effect), or naltrexone (antagonist, risk of precipitated withdrawal).
  • Buprenorphine is often combined with naloxone to deter IV misuse and can be prescribed from an office.
  • Alcohol Use Disorder (AUD): Naltrexone is first-line to reduce cravings.
  • Acamprosate is also first-line for AUD, especially with liver disease.
  • Disulfiram is a second-line aversive agent.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE